GlassScriptPhysician profile
Katherine Morse
NPI 1386371326
$7,324.50
in general payments reported to CMS, 2019-2025
40 companies · $3,551 in 2025
The $3,551 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,120 · 2024: $2,654 · 2025: $3,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,324.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,847.50 | 2023-2025 | |
| Janssen Biotech, INC. | $751.80 | 2024-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $737.72 | 2024-2025 | Entyvio, Eohilia |
| Aimmune Therapeutics, INC. | $417.06 | 2024-2025 | Vowst, Zenpep |
| Lilly USA, LLC | $341.15 | 2023-2024 | Mounjaro, Jardiance, Omvoh |
| Gilead Sciences, INC. | $318.87 | 2024-2025 | |
| Pfizer INC. | $303.12 | 2023-2025 | |
| Madrigal Pharmaceuticals | $297.39 | 2024-2025 | Rezdiffra, Resmetirom |
| Novo Nordisk INC | $226.56 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Ardelyx, INC. | $222.16 | 2024-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $215.43 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $185.85 | 2024-2025 | Trulance, Xifaxan, Relistor |
| Celltrion USA INC. | $181.59 | 2024-2025 | Vegzelma, Zymfentra |
| Genzyme Corporation | $180.39 | 2024-2025 | |
| Organon LLC | $145.78 | 2023-2025 | Nexplanon, Hadlima |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $135.22 | 2024-2025 | Dupixent |
| Enterra Medical, INC. | $85.29 | 2024-2025 | |
| Mylan Specialty L.P. | $65.97 | 2023 | Yupelri |
| Xeris Pharmaceuticals, INC. | $58.16 | 2023-2024 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $54.32 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $53.33 | 2023 | Breztri, Bevespi Aerosphere |
| Qol Medical, LLC | $47.35 | 2024 | Sucraid |
| Amgen INC. | $44.78 | 2023 | Prolia, Evenity, Repatha |
| Ipsen Biopharmaceuticals, INC | $42.69 | 2024-2025 | Iqirvo |
| Shield Therapeutics INC | $36.26 | 2023 | Accrufer |
| Fresenius Kabi USA, LLC | $35.93 | 2024 | Idacio |
| Sandoz INC. | $33.98 | 2024 | Hyrimoz |
| Orphalan INC | $27.33 | 2025 | Cuvrior |
| Edwards Lifesciences Corporation | $27.26 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Merck Sharp & Dohme LLC | $25.80 | 2024 | |
| Axsome Therapeutics, INC. | $25.22 | 2023 | Auvelity |
| Csl Behring | $24.81 | 2023 | Haegarda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.03 | 2023 | Tradjenta, Synjardy, Jardiance |
| Boston Scientific Corporation | $19.62 | 2023 | Wavewriter Alpha Prime 16 |
| Intercept Pharmaceuticals, INC. | $16.39 | 2024 | |
| Sanofi Pasteur INC. | $16.28 | 2023 | |
| Medtronic, INC. | $15.96 | 2025 | Interstim |
| Lundbeck LLC | $14.42 | 2023 | Vyepti |
| Nestle Healthcare Nutrition INC. | $14.27 | 2023 | |
| Sumitomo Pharma America, INC. | $10.46 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Morse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.